Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25877852 | 0.82 | ALDH1A1 (0.46) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL24141142 | 0.81 | ALDH1A1 (0.45) | MAPTKMT2AMEN1LMNAHPGD | |
| SCHEMBL25877652 | 0.81 | NAMPT (0.52) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL25877680 | 0.79 | SIRT2 (0.46) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL25877646 | 0.77 | KDR (0.53) | MAPTKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL25877550 | 0.75 | L3MBTL1 (0.48) | MAPTKMT2AMEN1LMNAHPGD | |
| SCHEMBL25877683 | 0.75 | HTT (0.53) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL5182303 | 0.74 | LMNA (0.69) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL7003484 | 0.74 | MEN1 (0.62) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL3341413 | 0.73 | LMNA (0.53) | MAPTKMT2AMEN1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2021263079-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | MAPT 3694/4885KMT2A 3032/4885MEN1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.